Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALIENT-AD: Leronlimab in Alzheimer's Disease
NCT07553338Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Apr 2026
- Primary completion
- Nov 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leronlimab in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI), sponsored by Weill Cornell Medicine. Primary endpoint: Mean change from baseline in whole-brain inflammation using 11C-DPA-713 Positron Emission Tomography (PET) at 13 weeks. Started Apr 2026; status: recruiting.
02
Drugs
leronlimab
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07553338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553338.